In recent years, the T1799A B-type Raf kinase (BRAF) mutation in thyroid cancer has
received enthusiastic investigation, and significant progress has been made toward …

Objective: To find out the most predictive staging system for papillary thyroid carcinoma
(PTC) currently available in the literature. Background: Various staging systems or risk group …

In the CLARINET study, lanreotide Autogel (depot in USA) significantly prolonged
progression-free survival (PFS) in patients with metastatic pancreatic/intestinal …

Context: Individualized management, incorporating papillary thyroid cancer (PTC) variant-
specific risk, is conceivably a useful treatment strategy for PTC, which awaits comprehensive …

Background Although recurrence and death can occur in patients with papillary thyroid
cancer (PTC) several years after being diagnosed, the necessary duration of follow-up for …

Encapsulated follicular variant of papillary thyroid carcinoma is a common thyroid gland
cancer, with a highly indolent behavior. Recently, reclassification as a non-malignant …

Background: There is conflicting literature regarding the association of the BRAF V600E
mutation and aggressive clinicopathological features of papillary thyroid cancer (PTC) …

Abstract BRAF (V600E) mutation is the most frequent genetic alteration in papillary thyroid
carcinomas (PTCs) that are 80–90% of all thyroid cancers. We evaluated the relationship …

Background: Recent studies have described an encapsulated and an infiltrative form of
follicular variant of papillary thyroid carcinoma (FVPTC). While encapsulated tumors have …

Background: Follicular variant of papillary thyroid carcinoma (FV-PTC) has been
increasingly diagnosed in recent years. However, little is known about its clinical behavior …